Search...
/
The Fly Cast
Press play to listen
Smarter market moves start here
Competitive Advantages
Novel Mechanism of Action: PRAX-562 targets T-type calcium channels, offering a differentiated approach for Essential Tremor compared to existing therapies and potentially leading to better efficacy and tolerability.
FDA Breakthrough Therapy Designation: The lead program, PRAX-562 for Essential Tremor, has received this designation, which can expedite development and regulatory review, potentially accelerating market entry.
Addressing Large Unmet Needs: Praxis focuses on CNS disorders like Essential Tremor and Focal Epilepsy, areas with significant patient populations and a lack of sufficiently effective or well-tolerated treatments.
Risks
Clinical Development Failure Risk: Praxis's drug candidates may fail to demonstrate safety or efficacy in ongoing or future clinical trials, leading to discontinuation of programs.
Regulatory Approval Uncertainty: Even with positive clinical data, Praxis may not obtain necessary regulatory approvals from agencies like the FDA, preventing commercialization of its product candidates.
Capital Requirements and Funding Dilution: Praxis will require substantial additional financing to fund its operations, which may not be available on favorable terms and could result in significant dilution for current shareholders.
Monday
Jun 22, 8:16 AM
Over a week ago
Jun 17, 4:30 PM
Jun 10, 3:35 PM
Jun 2, 12:00 PM
Jun 2, 8:05 AM
Jun 2, 7:46 AM
Jun 2, 7:35 AM
Jun 2, 7:17 AM
Jun 2, 6:52 AM
Jun 2, 6:11 AM
Jun 2, 4:29 AM
Jun 1, 4:47 PM
Jun 1, 4:45 PM
Jun 1, 4:19 PM
Jun 1, 4:10 PM
May 13, 9:43 AM
May 8, 9:37 AM
May 8, 8:53 AM
May 7, 9:05 AM
Apr 15, 8:46 AM
Apr 14, 7:32 AM
Apr 10, 5:37 AM